"We aim to achieve meaningful results as a platform company leading the 'Gene Therapy 3.0' era in the fields of gene therapy and next-generation nucleic acid therapeutics."
Samyang Biopharm is accelerating its efforts to secure global partnerships ahead of its participation in the world's largest biotech event, the Bio International Convention (Bio USA 2026). The company plans to leverage its next-generation drug delivery platform to achieve tangible results in the nucleic acid therapeutics and gene therapy sectors during the event.
According to industry sources on June 18, Samyang Biopharm will attend Bio USA, taking place from June 22 to 25 in San Diego, California, where it will hold business meetings with several global pharmaceutical and biotech companies.
Organized by the Biotechnology Innovation Organization (BIO), this event gathers approximately 20,000 industry professionals from around the world to discuss technology transfers, investments, and strategic partnerships.
This year marks Samyang Biopharm's fifth consecutive participation in the event. The company plans to explore collaboration opportunities centered around its core platform, 'SENS (Selectivity Enabling Nano Shell).' Reports indicate that it is pursuing partnership meetings with about 40 global companies.
SENS is a drug delivery technology designed to selectively transport nucleic acid-based therapeutics, such as short interfering RNA (siRNA) and messenger RNA (mRNA), to targeted cells in specific tissues. It is characterized by its ability to efficiently deliver drugs to various organs, including the liver, lungs, and brain, while minimizing off-target side effects. Additionally, it is designed using biodegradable polymers, allowing for repeated administration.
Building on this platform, Samyang Biopharm is expanding its research and development scope into next-generation nucleic acid therapeutics and gene therapies. The company is particularly focused on securing new modalities in areas such as in vivo chimeric antigen receptor T-cell (CAR-T) therapies, treatments targeting central nervous system (CNS) diseases, and new RNA cargo fields, while establishing a mid- to long-term pipeline.
A representative from Samyang Biopharm stated, "We plan to focus on securing partnerships for new drug development utilizing the SENS platform."
In February, Samyang Biopharm amended its articles of incorporation to increase its issuance limit for convertible bonds and bonds with warrants from 40 billion won to 100 billion won. This move is seen as a way to flexibly secure necessary funds during its business expansion process, including facility investments, new pipeline acquisitions, and external technology introductions.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.